{"id":1350,"date":"2016-02-01T12:02:00","date_gmt":"2016-02-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/kann-man-den-ergebnissen-der-rocket-af-studie-trauen"},"modified":"2016-02-01T12:02:00","modified_gmt":"2016-02-01T11:02:00","slug":"kann-man-den-ergebnissen-der-rocket-af-studie-trauen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/kann-man-den-ergebnissen-der-rocket-af-studie-trauen","title":{"rendered":"Kann man den Ergebnissen der ROCKET-AF-Studie trauen?"},"content":{"rendered":"<p>F\u00fcnf Jahre nach Ver\u00f6ffentlichung der Rocket-AF-Studie (1, 2), der wichtigsten und gr\u00f6\u00dften Phase-III-Studie zur Anwendung von Rivaroxaban bei Vorhofflimmern, kamen Zweifel an der internen Validit\u00e4t der Studie auf. Nach Angaben des British Medical Journal (BMJ; 3) wurde im Warfarin-Vergleichsarm ein unzuverl\u00e4ssiges Ger\u00e4t zur INR-Messung verwendet (INRatio Monitor System von Alere, vormals HemoSense). Probleme mit der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>F\u00fcnf Jahre nach Ver\u00f6ffentlichung der Rocket-AF-Studie (1, 2), der wichtigsten und gr\u00f6\u00dften Phase-III-Studie zur Anwendung von Rivaroxaban bei Vorhofflimmern, kamen Zweifel an der internen Validit\u00e4t der Studie auf. Nach Angaben des British Medical Journal (BMJ; 3) wurde im Warfarin-Vergleichsarm ein unzuverl\u00e4ssiges Ger\u00e4t zur INR-Messung verwendet (INRatio Monitor System von Alere, vormals HemoSense). Probleme mit der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,137,1314,1312,1284,1283,187,1141,1328,1327,183,2304,3254,1409,181,136],"class_list":["post-1350","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-antikoagulanzien","tag-direkte-orale-antikoagulanzien","tag-doak","tag-ema","tag-europaeische-arzneimittel-agentur","tag-herzrhythmusstoerungen","tag-klinische-studien","tag-neue-orale-antikoagulanzien","tag-noak","tag-rhythmusstoerungen","tag-rivaroxaban","tag-rocket-af-studie","tag-studien","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1350"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1350\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}